Screener
Recursion Pharmaceuticals, Inc. RXRX Restricted Cash Current
Restricted Cash Current at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s restricted cash current?
- Recursion Pharmaceuticals, Inc. (RXRX) reported restricted cash current of $5.39M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s restricted cash current changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s restricted cash current increased by 73.4% year-over-year, from $3.11M to $5.39M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s restricted cash current?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s restricted cash current has grown at a 18.1% compound annual growth rate (CAGR), from $2M to $4.59M.
- What does restricted cash current mean?
- Restricted Cash Current as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s restricted cash current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude